Date: 2017-03-24
Type of information: Development agreement
Compound: small molecule protein degraders as therapeutic agents to remove certain disease-causing proteins
Company: C4 Therapeutics (USA - MA) Calico (USA - CA)
Therapeutic area: Cancer - Oncology
Type agreement: development commercialisation
Action mechanism:
Disease: diseases of aging, including cancer
Details: * On March 23, 2017, C4 Therapeutics (C4T) and Calico announced a five-year collaboration to discover, develop, and commercialize therapies for treating diseases of aging, including cancer. Under the terms of the agreement, the parties will leverage C4T’s expertise and capabilities in targeted protein degradation to jointly discover and advance small molecule protein degraders as therapeutic agents to remove certain disease-causing proteins. The partnership will pursue preclinical research and Calico will be responsible for subsequent clinical development and commercialization of resulting products that may emerge from the collaboration. C4 Therapeutics is developing a new class of drugs based on Targeted Protein Degradation (TPD) to address a broad range of life-threatening and life-impairing diseases. C4T’s Degronimid™ platform uses small molecule drugs to direct the machinery of the ubiquitin-proteasome system to selectively degrade disease-relevant proteins for therapeutic benefit.
Financial terms:
Latest news:
